Holen Sie sich die Stockscreener-App
4.815
2.13%
-0.105
Handel nachbörslich:
4.80
-0.015
-0.31%
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, with key H2 catalysts - TradingView
[EFFECT] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara’s cell therapy shows treatment durability in mid-stage NMIBC study - MSN
Piper Sandler initiates coverage of Protara Therapeutics (TARA) with overweight recommendation - MSN
Protara Therapeutics Inc stock (US87612E1064): analyst optimism contrasts with volatile share price - AD HOC NEWS
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $24 to $28 - Moomoo
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV) - The Globe and Mail
Piper Sandler Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $24 - Moomoo
What's Driving Protara's Recent Surge - Kavout
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic MalformationsSlideshow (NASDAQ:TARA) 2026-05-20 - Seeking Alpha
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $25 to $27 - Moomoo
TARA Maintained by Oppenheimer -- Price Target Raised to $28.00 - GuruFocus
Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating - Moomoo
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Cantor Fitzgerald reiterates Protara Therapeutics stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Protara Therapeutics stock rating - Investing.com
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - The Manila Times
H.C. Wainwright reiterates Protara stock rating citing LM data By Investing.com - Investing.com Canada
J.P. Morgan Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Protara Therapeutics reports 55% complete response rate in bladder cancer study - MSN
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 - Sahm
protara therapeutics, inc. Earnings dates - RTTNews
Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program - Quiver Quantitative
Protara Therapeutics to Host Virtual Investor Webinar to - GlobeNewswire
Inside Protara’s May 19 webinar on lymphatic malformations and TARA-002 - Stock Titan
Protara Therapeutics Inc stock (US87612E1064): bladder cancer data put small-cap biotech in focus - AD HOC NEWS
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Protara Therapeutics (TARA) Unveils Promising Phase 2 Trial Resu - GuruFocus
Janus Henderson (TARA) disclosed 5.21M-share, 9.6% stake in Protara - Stock Titan
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study - Benzinga
Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA) - The Globe and Mail
Protara reports 12-month data for bladder cancer therapy By Investing.com - Investing.com South Africa
Protara reports 12-month data for bladder cancer therapy - Investing.com
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC - The Manila Times
Protara Therapeutics announces positive updated 12-month data demonstrating durable responses - marketscreener.com
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses - TradingView
TARA Maintained by JP Morgan -- Price Target Lowered to $26.00 - GuruFocus
Protara Therapeutics 1Q Research and Development Expenses $13.6M >TARA - Moomoo
Protara's TARA-002 Shows Durable Bladder Cancer Response at 12 Months - BriefGlance
Protara Therapeutics stock (US87612E1064): Q1 earnings beat estimates with narrower loss - AD HOC NEWS
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $21 to $30 - Moomoo
MSN Money - MSN
Protara Therapeutics, Inc. Q1 2026 Financial Report: Key Updates, Forward-Looking Statements, and Financial Highlights - Minichart
Protara Therapeutics (NASDAQ: TARA) files $300M shelf registration for future offerings - Stock Titan
Protara Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Protara Therapeutics (TARA) Prepares for BLA Submission Followin - GuruFocus
Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 for Lymphatic Malformations and NMIBC with BLA Planned for 2027 - Minichart
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Protara Therapeutics 1Q Loss $17.8M >TARA - Moomoo
Protara Therapeutics, Inc. Q1 2026: Net income $(17.8M), EPS $(0.31) — 10-Q Summary - TradingView
Protara Therapeutics reports Q1 2026 net loss $17.8M; cash and investments $177.4M - TradingView
Protara Therapeutics (NASDAQ: TARA) widens Q1 loss while advancing late-stage pipeline - Stock Titan
Protara Therapeutics: Q1 Earnings Snapshot - marketscreener.com
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):